Therapeutic effect of mesenchymal stem cells in an animal model of Alzheimer’s disease evaluated by β-amyloid positron emission tomography imaging

Park, Bok-Nam; Kim, Jang-Hee; Lim, Tae Sung; Kim, Taegyu; Yoon, Bok Seon; Son, Keoung Sun; Yoon, Joon-Kee; An, Young‐Sil

doi:10.1177/0004867420917467

Cited by 18 publications

(6 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, MSCs can contribute to the clearance of Aβ via differentiating itself into microglia cells or activating the enrolment of endogenous microglia cells [34,35,36]. Transplanting BM-MSCs to AD models can contribute to the clearance of Aβ, as reported by Jong et al The BM-MSCs transplant being investigated by them successfully increase and induce the amount of activated microglia, which supports the theory that BM-MSC transplant is an effective therapeutic tool in eliminating Aβ plaque.…”

Section: Mesenchymal Stem Cells (Mscs)mentioning

confidence: 55%

An overview of stem cell-based therapy towards the treatment of Alzheimer’s disease

Chen

2023

Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022)

View full text Add to dashboard Cite

The classic pharmacological approach toward Alzheimer's disease treatment uses acetylcholinesterase inhibitors (AChEIs), where patients' behavior and cognitive symptoms can be treated. However, the pharmacological approaches available can only relieve patients' symptoms to some extent instead of acting as a cure. With the recent advancements in regenerative medicine, extensive pre-clinical studies have been conducted to test if stem cell therapy can be a cure for Alzheimer's disease. The stem cell type being investigated through the treatment of Alzheimer's disease includes embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and neural stem cells (NSCs). This review briefly introduces the causes and pharmacological approach to Alzheimer's disease, highlights some of the critical results reported from the pre-clinical studies and discusses the challenges associated with each type of cell when used as a source for conducting stem cell therapy for Alzheimer's disease. Although preclinical studies have proved relevant mediated effects to Alzheimer's disease can be induced by stem cell therapy.

show abstract

Section: Mesenchymal Stem Cells (Mscs)mentioning

confidence: 55%

An overview of stem cell-based therapy towards the treatment of Alzheimer’s disease

Chen

2023

Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022)

View full text Add to dashboard Cite

show abstract

“…These stem cells have a high expansion capacity, low immunogenicity, and low carcinogenic potential [ 177 , 178 ]. With regard to AD pathology in mice, MSCs have been shown to reduce Aβ plaque size, enhance Aβ clearance and reduce Aβ expression [ 179 , 180 ]. MSCs can also alter innate and adaptive immune responses by modulating neuroprotective cytokines such as interleukin (IL)-10 and downregulating pro-inflammatory cytokines such as TNF-α and IL-1β [ 181 ].…”

Section: Stem Cellsmentioning

confidence: 99%

Alzheimer’s Disease Treatment: The Search for a Breakthrough

et al. 2023

View full text Add to dashboard Cite

As the search for modalities to cure Alzheimer’s disease (AD) has made slow progress, research has now turned to innovative pathways involving neural and peripheral inflammation and neuro-regeneration. Widely used AD treatments provide only symptomatic relief without changing the disease course. The recently FDA-approved anti-amyloid drugs, aducanumab and lecanemab, have demonstrated unclear real-world efficacy with a substantial side effect profile. Interest is growing in targeting the early stages of AD before irreversible pathologic changes so that cognitive function and neuronal viability can be preserved. Neuroinflammation is a fundamental feature of AD that involves complex relationships among cerebral immune cells and pro-inflammatory cytokines, which could be altered pharmacologically by AD therapy. Here, we provide an overview of the manipulations attempted in pre-clinical experiments. These include inhibition of microglial receptors, attenuation of inflammation and enhancement of toxin-clearing autophagy. In addition, modulation of the microbiome-brain-gut axis, dietary changes, and increased mental and physical exercise are under evaluation as ways to optimize brain health. As the scientific and medical communities work together, new solutions may be on the horizon to slow or halt AD progression.

show abstract

“…But increasing evidence have shown transplanted MSCs can only survive in the host for a very limited amount of time. Intravenously administered MSCs mostly are trapped in the lung and the spleen (Park B. N. et al, 2018;Kim et al, 2020;Park et al, 2020;Hernandez and Garcia, 2021). Now it is generally believed transplanted MSCs mainly function through paracrine effects (Walker and Jucker, 2015;Duncan and Valenzuela, 2017;Guo et al, 2020;Kim et al, 2020;Liu et al, 2021).…”

Section: Proposed Mechanisms Of Action Of Mesenchymal Stem Cells Ther...mentioning

confidence: 99%

Alzheimer’s Disease: From Pathogenesis to Mesenchymal Stem Cell Therapy – Bridging the Missing Link

Wang

2022

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease worldwide. With the increasing trend of population aging, the estimated number of AD continues to climb, causing enormous medical, social and economic burden to the society. Currently, no drug is available to cure the disease or slow down its progression. There is an urgent need to improve our understanding on the pathogenesis of AD and develop novel therapy to combat it. Despite the two well-known pathological hallmarks (extracellular amyloid plaques and intracellular Neurofibrillary Tangles), the exact mechanisms for selective degeneration and loss of neurons and synapses in AD remain to be elucidated. Cumulative studies have shown neuroinflammation plays a central role in pathogenesis of AD. Neuroinflammation is actively involved both in the onset and the subsequent progression of AD. Microglia are the central player in AD neuroinflammation. In this review, we first introduced the different theories proposed for the pathogenesis of AD, focusing on neuroinflammation, especially on microglia, systemic inflammation, and peripheral and central immune system crosstalk. We explored the possible mechanisms of action of stem cell therapy, which is the only treatment modality so far that has pleiotropic effects and can target multiple mechanisms in AD. Mesenchymal stem cells are currently the most widely used stem cell type in AD clinical trials. We summarized the ongoing major mesenchymal stem cell clinical trials in AD and showed how translational stem cell therapy is bridging the gap between basic science and clinical intervention in this devastating disorder.

show abstract

Therapeutic effect of mesenchymal stem cells in an animal model of Alzheimer’s disease evaluated by β-amyloid positron emission tomography imaging

Cited by 18 publications

References 50 publications

An overview of stem cell-based therapy towards the treatment of Alzheimer’s disease

An overview of stem cell-based therapy towards the treatment of Alzheimer’s disease

Alzheimer’s Disease Treatment: The Search for a Breakthrough

Alzheimer’s Disease: From Pathogenesis to Mesenchymal Stem Cell Therapy – Bridging the Missing Link

Contact Info

Product

Resources

About